Early Supported Discharge and Enhanced Homecare After Emergency Department Admission for Acute Exacerbation of COPD

Overview

The prevalence of chronic obstructive pulmonary disease (COPD) is between 8 and 15% of the adult population in 2010. This prevalence is expected to increase over the coming decades as the population ages and exposure to the risk factors for the disease continues. The evolution of COPD is marked by the occurrence of exacerbations of varying severity responsible for 1% of emergency department admission. Thus,95% of COPD patients admitted to emergency department for exacerbation are hospitalized.

Several recent studies seem to show that an early discharge from hospital with home care can reduce the rate of rehospitalisation and mortality of COPD patients. These preliminary data on low numbers need to be confirmed. In addition, it seems necessary to identify the phenotypes of patients who benefit most from these early exits.

Exadom project (supported by Rhône-Alpes-Auvergne Regional Health Authorities (ARS), AstraZeneca and Grenoble Alpes University Hospital) aims to establish a safe and effective way of discharging patients by providing enhanced home-based care for AECOPD.

Full Title of Study: “EXADOM: Early Supported Discharge and Enhanced Homecare After Emergency Department Admission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2022

Detailed Description

Exadom project (supported by Rhône-Alpes-Auvergne Regional Health Authorities (ARS) , Grenoble Alpes University Hospital) aims to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.

This program implements ambulatory care immediately after leaving the emergency department with a main goal of reducing hospital readmission during the first month. The home-based support includes daily visits at home conducted by the home care provider's nurses from day 1 to day 7, telephone calls at days 14 and 21 and a final home visit one month after discharge from the emergency department. Blood samples will be collected at inclusion, day 7 and one month during home visit and urine samples at inclusion, day 2, day 4 and one month during home visit .Telephone follow-up at 3, 6 months and one year.

Interventions

  • Other: Prevention
    • The purpose is to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.

Arms, Groups and Cohorts

  • Other: COPD patient
    • Prevention of re-hospitalization rate for Early supported discharge and enhanced homecare to patient admited for COPD exacerbation

Clinical Trial Outcome Measures

Primary Measures

  • Rate of hospitalizations
    • Time Frame: 90 days
    • number of an hospitalization being an entry in any hospital or clinic , whatever the length of the stay

Secondary Measures

  • Rate of all cause of hospitalizations
    • Time Frame: 6 months and one year
    • number of an hospitalization being an entry in any hospital or clinic , whatever the length of the stay for all cause
  • hospitalization rate for COPD exacerbation aggravation
    • Time Frame: 3,6 and 12 months
    • number of an hospitalization being an entry in any hospital or clinic , whatever the length of the stay for COPD exacerbation aggravation
  • Hospitalization rate for worsening for cardio-respiratory symptoms
    • Time Frame: one year
    • number of hospitalizations due to myocardial infarction, cardiac failure, stroke
  • Mortality
    • Time Frame: 3, 6 and 12 months
    • number of death
  • Determinants of hospitalization
    • Time Frame: 30 days
    • measures of biological and clinical markers collected at baseline and at day 30
  • Differential of biological and clinical markers
    • Time Frame: 30 days
    • Differential measurements of biological and clinical markers between day 30 and at inclusion
  • Differential of medical average cost per patient
    • Time Frame: 3 months
    • comparaison between early discharge patient with ambulatory care group and patient with standard care (historical cohort)
  • Acceptance rate of early ambulatory care
    • Time Frame: 1 year
    • Measured on the basis of a refusal register

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 40 years
  • Current or former smoker, with at least 10 pack-years
  • previous history of COPD with concordant spirometry results
  • Admission to the emergency department for an exacerbation defined as an acute event which is characterized by a degradation of respiratory symptoms greater than the usual daily variations and requiring a change in therapeutic management
  • Patient with mild exacerbation characterized by a DECAF score at 0 or 1. (DECAF score: Dyspnea, Eosinopenia, Consolidation on chest x-ray, Acidaemia, and atrial Fibrillation. One point for each criterion. Mortality at one month is less than 3% if the DECAF score is 0 or 1).
  • Residence within 30km of Grenoble Alps University Hospital
  • Patient legally able to give consent
  • Person affiliated to a medical insurance

Exclusion Criteria

  • Dementia or non-communicating patient in French language
  • Patient unable to call the emergency department at any time in case of sudden worsening
  • Pregnancy or breastfeeding woman
  • patient under administrative or judicial supervision
  • DECAF Score > 1. Patient's with DECAF score > 1 are considered at too high risk of mortality to be managed at home (they are usually hospitalized).

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Grenoble
  • Collaborator
    • AGIR à Dom
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Maxime MAIGNAN, PhD, 0033476766784, mmaignan@chu-grenoble.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.